About: covid:PMC7422632

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: covid:PMC7422632 Goto Sponge NotDistinct Permalink

An Entity of Type : owl:Thing, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
Creator	Stein, Cy Agarwal, Neeraj Babiker, Hani Barata, Pedro Bryce, Alan Garje, Rohan Gerendash, Benjamin Hatton, Whitley Jaeger, Ellen Kiedrowski, Lesli Layton, Jodi Ledet, Elisa Lewis, Brian Nussenzveig, Roberto Sartor, Oliver Saylor, Philip
is schema:about of	named entity 'PEMBROLIZUMAB' named entity 'metastatic prostate cancer' named entity 'ctDNA' named entity 'pembrolizumab' named entity 'case series' named entity 'hormonal therapies' named entity 'MSI-H' named entity 'PSA' named entity 'MSI-H' named entity 'circulating tumor DNA' named entity 'biomarker' named entity '14.5' named entity 'repeated sequences' named entity 'MSI-H' named entity 'tumors' named entity 'PD-1 inhibitors' named entity 'Caucasian' named entity 'microsatellite' named entity 'cell-free DNA' named entity 'BRCA1' named entity 'PSA' named entity 'MSI-H' named entity 'single nucleotide variants' named entity 'case series' named entity 'checkpoint blockade' named entity 'MSI-H' named entity 'MSI-H' named entity 'clinical characteristics' named entity 'CRPC' named entity 'MSI-H' named entity 'pembrolizumab' named entity 'biomarkers' named entity 'biomarkers' named entity 'PD-L1' named entity 'chemotherapy' named entity 'lymph nodes' named entity 'phase II study' named entity 'plasma' named entity 'liquid biopsy' named entity 'MSI-H' named entity 'metastatic prostate cancer' named entity 'DNA sequence' named entity 'SNVs' named entity '21%' named entity 'DNA repair' named entity 'BRCA2' named entity 'CRPC' named entity 'adverse events' named entity 'microsatellite' named entity 'selection bias' named entity '0.9' named entity 'pembrolizumab' named entity 'immune checkpoint inhibitors' named entity 'oncology' named entity 'programmed death ligand 1' named entity 'SNVs' named entity 'MSI-H' named entity 'prostate cancer' named entity 'PSA' named entity 'biomarkers' named entity 'hormonal therapies' named entity 'pembrolizumab' named entity '2.6' named entity 'PD-L1' named entity 'plasma' named entity 'metastatic prostate cancer' named entity 'indels' named entity 'microsatellite instability' named entity 'ctDNA' named entity 'cabozantinib' named entity 'ATM' named entity 'cytotoxic T-lymphocyte-associated protein 4' named entity 'advanced prostate cancer' named entity 'median follow-up' named entity 'pembrolizumab' named entity 'cell therapies' named entity 'tumor' named entity 'Group 3' named entity 'US Food and Drug Administration' named entity '95% CI' named entity 'Prostate Cancer' named entity 'phenotype' named entity 'lymph nodes' named entity 'castrate'

Attributes

Values

Creator

Stein, Cy
Agarwal, Neeraj
Babiker, Hani
Barata, Pedro
Bryce, Alan
Garje, Rohan
Gerendash, Benjamin
Hatton, Whitley
Jaeger, Ellen
Kiedrowski, Lesli
Layton, Jodi
Ledet, Elisa
Lewis, Brian
Nussenzveig, Roberto
Sartor, Oliver
Saylor, Philip

is schema:about of

named entity 'PEMBROLIZUMAB'
named entity 'metastatic prostate cancer'
named entity 'ctDNA'
named entity 'pembrolizumab'
named entity 'case series'
named entity 'hormonal therapies'
named entity 'MSI-H'
named entity 'PSA'
named entity 'MSI-H'
named entity 'circulating tumor DNA'
named entity 'biomarker'
named entity '14.5'
named entity 'repeated sequences'
named entity 'MSI-H'
named entity 'tumors'
named entity 'PD-1 inhibitors'
named entity 'Caucasian'
named entity 'microsatellite'
named entity 'cell-free DNA'
named entity 'BRCA1'
named entity 'PSA'
named entity 'MSI-H'
named entity 'single nucleotide variants'
named entity 'case series'
named entity 'checkpoint blockade'
named entity 'MSI-H'
named entity 'MSI-H'
named entity 'clinical characteristics'
named entity 'CRPC'
named entity 'MSI-H'
named entity 'pembrolizumab'
named entity 'biomarkers'
named entity 'biomarkers'
named entity 'PD-L1'
named entity 'chemotherapy'
named entity 'lymph nodes'
named entity 'phase II study'
named entity 'plasma'
named entity 'liquid biopsy'
named entity 'MSI-H'
named entity 'metastatic prostate cancer'
named entity 'DNA sequence'
named entity 'SNVs'
named entity '21%'
named entity 'DNA repair'
named entity 'BRCA2'
named entity 'CRPC'
named entity 'adverse events'
named entity 'microsatellite'
named entity 'selection bias'
named entity '0.9'
named entity 'pembrolizumab'
named entity 'immune checkpoint inhibitors'
named entity 'oncology'
named entity 'programmed death ligand 1'
named entity 'SNVs'
named entity 'MSI-H'
named entity 'prostate cancer'
named entity 'PSA'
named entity 'biomarkers'
named entity 'hormonal therapies'
named entity 'pembrolizumab'
named entity '2.6'
named entity 'PD-L1'
named entity 'plasma'
named entity 'metastatic prostate cancer'
named entity 'indels'
named entity 'microsatellite instability'
named entity 'ctDNA'
named entity 'cabozantinib'
named entity 'ATM'
named entity 'cytotoxic T-lymphocyte-associated protein 4'
named entity 'advanced prostate cancer'
named entity 'median follow-up'
named entity 'pembrolizumab'
named entity 'cell therapies'
named entity 'tumor'
named entity 'Group 3'
named entity 'US Food and Drug Administration'
named entity '95% CI'
named entity 'Prostate Cancer'
named entity 'phenotype'
named entity 'lymph nodes'
named entity 'castrate'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software